Immuneering Corp Ordinary Shares Class A IMRX 深 滬
已收盤 09-05 16:00:00 美东时间
5.51
+0.050
+0.92%
華盛通- 最 高5.6179
- 今 開5.48
- 成交量 59.40万股
- 最 低 5.17
- 昨 收 5.46
- 總市值 2.35亿
- 52周最高 6.35
- 市盈率 靜 --
- 換手率 1.39%
- 52周最低 1.10
- 委 比 -19.66%
- 總股本 4264.80万
- 歷史最高 33.99
- 量 比 0.93
- 振 幅 8.20%
- 歷史最低 1.00
- 每 手 1
- 風險率 2.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 大麻股持续获市场追捧！Tilray大涨20%；生物制药公司IMRX大涨21%
AEHR升逾35%，公司获得来自超大规模云服务商的AI芯片测试订单；大麻股持续获市场追捧！Tilray大涨20%；生物制药公司IMRX大涨21%，公司与礼来达成协议>>
08-26 13:43
Immuneering Corporation Enters Agreement With Eli Lilly To Evaluate Its Lead Drug Candidate, Atebimetinib , In Combination With Lilly's Kras G12c Inhibitor, Olomorasib, In A Planned Phase 2 Trial For Patients With Advanced KRAS G12c-Mutant Non-Small Cell Lung Cancer
Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its
08-25 20:05
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
Immuneering Corporation announced a clinical supply agreement with Eli Lilly for its KRAS G12C inhibitor olomorasib to evaluate in combination with its MEK inhibitor atebimetinib in a planned Phase 2 trial for advanced KRAS G12C-mutant non-small cell lung cancer. The combination aims to achieve a vertical blockade of the RAS-MAPK pathway, potentially improving outcomes for patients with limited treatment options. Earlier this year, Immuneering al...
08-25 12:00
美股牛股 | “MEME股”大热门OpenDoor再度飙涨11%！小鹏绩后大涨11.7%，Q2营收创单季度历史新高
“MEME股”OpenDoor再度飙涨11%！美国7月房屋销售意外上升；小鹏绩后大涨11.7%，Q2营收创单季度历史新高>>
08-22 17:55
Immuneering Announces $25 Million Private Placement
Immuneering Corporation announced a $25 million private placement to institutional investors to fund its cancer drug development, including atebimetinib for pancreatic cancer. Recent trial data showed exceptional 6-month overall survival (94%) compared to standard treatment (67%). The financing supports advancing atebimetinib in the MAPK pathway.
08-21 12:00
Immuneering shares are trading higher after the company reported a Q2 EPS beat and announced it has filed for a $300 million mixed-shelf offering.
Immuneering shares are trading higher after the company reported a Q2 EPS beat ...
08-16 01:37
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $13 price target.
08-15 04:36
Immuneering Q2 EPS $(0.40) Beats $(0.41) Estimate
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.41) by 3.61 percent. This is a 14.89 percent increase over losses of $(0.47) per share from the
08-14 04:38
